Lupin Ltd. on Thursday, December 4, said it has inked an exclusive licensing agreement with US-based Valorum Biologics for its biosimilar Armlupeg (pegfilgrastim-unne).

As per the agreement, Valorum will advance the commercialisation and distribution of Amlupeg in the US. Lupin will manufacture and supply the product and will receive an upfront licence fee and a royalty payment on net sales.

Pegfilgrastim-unne is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy.

"We look forward to strengthening our presence in the US biosimilars market and building on our momentum as a global leader in developing and commercialising important biosimilar medicines," Spiro Gavaris, president of US Generics, Lupin, said.

On Monda

See Full Page